Search

REVOLUTION Medicines Inc

Slēgts

SektorsVeselības aprūpe

209.47 -0.26

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

208.08

Max

210.19

Galvenie mērījumi

By Trading Economics

Ienākumi

-644M

-1.1B

EPS

-2.34

Darbinieki

883

EBITDA

-184M

-621M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+18.64% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 4. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

5.3B

44B

Iepriekšējā atvēršanas cena

209.73

Iepriekšējā slēgšanas cena

209.47

Ziņu noskaņojums

By Acuity

31%

69%

68 / 339 Rangs Healthcare

REVOLUTION Medicines Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. sept. 19:16 UTC

News

Revolution Medicines Inc shares are higher after positive Phase 1/2 trial results for RASONQUE in advanced RAS mutant non-small cell lung cancer were published.

2026. g. 2. sept. 23:51 UTC

News

Revolution Medicines shares rise in after-market trading following positive Phase 1/2 data on RASONQUE for advanced RAS mutant non-small cell lung cancer.

2026. g. 1. sept. 23:06 UTC

Revolution Medicines Inc shares are higher in after-market trading, maintaining a stable performance since Tuesday's close despite earlier session volatility.

2026. g. 31. aug. 20:07 UTC

Correlated Moves
News

Revolution Medicines Inc shares are lower amid broader market pressures and concerns from the Jackson Hole Economic Symposium regarding inflation and monetary policy tightening.

2026. g. 28. aug. 20:02 UTC

Social Media
News

Revolution Medicines shares are lower amid significant selling pressure, despite recent price target increases by UBS and others for its drug RASONQUE.

2026. g. 27. aug. 23:02 UTC

News

Revolution Medicines Inc shares are higher in after-market trading following FDA approval of RASONQUE for metastatic pancreatic cancer, discussed during an August 26 conference call.

2026. g. 26. aug. 23:21 UTC

News
Social Media

Oppenheimer raised Revolution Medicines' price target to $260, citing FDA approval of RASONQUE for advanced pancreatic cancer, as shares trade higher in after-market hours.

2026. g. 25. aug. 20:07 UTC

News

Revolution Medicines Inc received a "Moderate Buy" rating from brokerages. Needham raised its price target to $240, while shares are trading roughly flat.

2026. g. 24. aug. 20:06 UTC

Revolution Medicines Inc shares are higher today, recovering from an earlier low. The stock has gained since Friday's close amid rising oil prices.

2026. g. 21. aug. 19:46 UTC

News

Revolution Medicines shares are lower today as Bernstein raised its price target to $179, continuing a trend of three consecutive daily declines.

2026. g. 20. aug. 23:26 UTC

Revolution Medicines Inc. shares were roughly flat in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

2026. g. 19. aug. 19:46 UTC

News

Revolution Medicines Inc shares are lower Wednesday, pulling back after reaching a session high. The stock has declined since Tuesday's close.

2026. g. 17. aug. 19:51 UTC

Social Media

Revolution Medicines shares are higher since Friday's close as Baker Bros boosts its stake to 11.4 million shares, valued at $2 billion.

2026. g. 13. aug. 19:36 UTC

Revolution Medicines Inc shares are lower, reaching a session low earlier. This decline follows a cumulative drop since Wednesday's close.

2026. g. 12. aug. 23:16 UTC

Revolution Medicines shares declined in after-market trading, despite earlier gains. The Consumer Price Index report showed a modest rise in consumer prices today.

2026. g. 11. aug. 19:36 UTC

News

Revolution Medicines Inc is trading lower as broader geopolitical tensions and upcoming U.S. inflation reports weigh on market sentiment.

2026. g. 10. aug. 23:51 UTC

Revolution Medicines Inc. shares were roughly flat in after-market hours, maintaining a position above the 20-day moving average and near the one-month range's upper end.

2026. g. 7. aug. 19:11 UTC

News

Revolution Medicines Inc shares are higher as the company plans a Phase 3 study and Wedbush raises its price target to $201 from $192.

2026. g. 6. aug. 19:36 UTC

Social Media
News

Revolution Medicines Inc is trading higher as RBC Capital and Evercore ISI raise price targets, reflecting growing confidence in the company's clinical pipeline.

2026. g. 5. aug. 23:02 UTC

Social Media
News

Revolution Medicines shares lower in after-market trading following a second-quarter loss of $644.4 million and an EPS of -$3.06, missing estimates.

2026. g. 4. aug. 23:06 UTC

Revolution Medicines shares are lower in after-market trading, settling near Tuesday's close. The stock remains above its 20-day moving average.

2026. g. 3. aug. 23:26 UTC

Revolution Medicines Inc shares are trading higher in after-market hours. Broader market sentiment is positive, influenced by declining oil prices and reduced inflation concerns.

2026. g. 31. jūl. 20:06 UTC

Revolution Medicines Inc. shares are lower amid broader market volatility and rising U.S. Treasury yields, which have heightened inflation concerns and interest rate expectations.

2026. g. 30. jūl. 22:41 UTC

Revolution Medicines Inc. shares are lower in after-market trading, declining since Thursday's close amid fluctuations in bond yields and Fed policy uncertainty.

2026. g. 29. jūl. 17:02 UTC

Revolution Medicines Inc shares are lower, continuing a four-session decline with unusually high trading volume. The stock remains below its 20-day moving average.

2026. g. 28. jūl. 19:02 UTC

Revolution Medicines Inc shares are lower today, continuing a decline since Monday amid negative broader market sentiment following significant drops in Asian markets.

2026. g. 27. jūl. 20:06 UTC

Revolution Medicines Inc shares are lower amid broader market dynamics, including a decline in oil prices and falling Treasury yields ahead of the Federal Reserve meeting.

2026. g. 24. jūl. 18:26 UTC

Social Media
News

Revolution Medicines shares are lower amid broader market sentiment, despite RJ's increased price target of $230 and positive FDA news on daraxonrasib.

2026. g. 22. jūl. 18:26 UTC

Revolution Medicines Inc shares are higher today amid broader geopolitical tensions affecting market sentiment, despite no specific company news driving the movement.

2026. g. 21. jūl. 17:16 UTC

Revolution Medicines Inc shares are higher today, reflecting gains since Monday amid supportive market conditions and positive sentiment from Asian markets and easing oil prices.

Salīdzinājums

Cenas izmaiņa

REVOLUTION Medicines Inc Prognoze

Cenas mērķis

By TipRanks

18.64% augšup

Prognoze 12 mēnešiem

Vidējais 249.16 USD  18.64%

Augstākais 320 USD

Zemākais 179 USD

Pamatojoties uz 21 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi REVOLUTION Medicines Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

21 ratings

20

Pirkt

1

Turēt

0

Pārdot

Noskaņojums

By Acuity

68 / 339 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
help-icon Live chat